iX Biopharma Ltd. (SGX:42C)

Market Cap	16.87M
Revenue (ttm)	7.00M
Net Income (ttm)	-9.72M
Shares Out	887.96M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	464,000
Average Volume	364,070
Open	0.0190
Previous Close	0.0200
Day's Range	0.0190 - 0.0190
52-Week Range	0.0150 - 0.0290
Beta	0.30
RSI	51.26
Earnings Date	Aug 21, 2025

About Chimerix

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 42
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 42C

Financial Performance

In 2024, iX Biopharma's revenue was 5.96 million, an increase of 0.78% compared to the previous year's 5.91 million. Losses were -10.79 million, 12.3% more than in 2023.